Document is current
Any future updates will be listed below
-
Authors
Barton, Brendan M.
Son, Francheska
Verma, Akanksha
Bal, Saswat Kumar
Tang, Qianzi
Wang, Rui https://orcid.org/0000-0002-6842-119X
Umphred-Wilson, Katharine
Khan, Rehan https://orcid.org/0000-0001-6035-4159
Trichka, Josephine
Dong, Han
Lentucci, Claudia
Chen, Xi https://orcid.org/0000-0003-2894-0363
Chen, Yinghua
Hong, Yuning https://orcid.org/0000-0002-8085-1651
Duy, Cihangir
Elemento, Olivier https://orcid.org/0000-0002-8061-9617
Melnick, Ari M. https://orcid.org/0000-0002-8074-2287
Cao, Jin
Chen, Xi https://orcid.org/0000-0002-7995-6202
Glimcher, Laurie H. https://orcid.org/0000-0002-4971-0404
Adoro, Stanley https://orcid.org/0000-0001-9092-5960
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-19-025-01-DDC)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K22 CA 218467, R01 CA198089, R37CA228304)
U.S. Department of Health & Human Services | National Institutes of Health (ZIA BC 01213)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (T32 AI089474)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008056)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL146642)
U.S. Department of Defense (W81XWH1910524)
- License Information
-
More Information
Article History
Received: 27 December 2021
Accepted: 10 December 2024
First Online: 9 January 2025
Competing interests
: L.H.G. is a former Director of Bristol Myers Squibb and the Waters Corporation and currently serves on the Board of Directors of GlaxoSmithKline Pharmaceuticals and Analog Devices. L.H.G. also serves on the scientific advisory boards of Repare Therapeutics, Abpro Therapeutics and Kaleido Therapeutics. A.M.M. receives research funding from Janssen, Daiichi Sankyo and Sanofi; has consulted for Epizyme, Constellation, BMI and Exo-Therapeutics; and is a scientific advisor to KDAC. A.V. is a current employee of Volastra Therapeutics. All other authors declare no competing interests.
